Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Plus HAIC (OXRI) for Barcelona Stage C HCC
NCT04597970Phase 2
Key facts
- Status
- Unknown
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Sponsor
- Peking University Cancer Hospital & Institute
- Modality
- DNA Intercalators/Alkylators
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and raltitrexed in hepatocellular carcinoma (HCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Objective Response Rate at 6 months, Disease Control Rate at 6 months and 2 more. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
cTACE-HAIC(oxaliplatin and raltitrexed)
Transarterial chemoembolization plus Hepatic Arterial Infusion Chemotherapy with oxaliplatin and raltitrexed
03
Who it enrols
Patients with BCLC stage C HCC who failed first-line treatment, Child-Pugh A or B7, and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Disease Control Rate
Progression-Free Survival
Safety
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT04597970.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04597970.